Expanding the therapeutic horizon of <sup>177</sup>Lu-DOTATATE: a review of current evidence.

51 Mirvis et al reported that patients with bronchial NETs who were treated with 177 Lu-DOTATATE had a median PFS of 18 months, which is longer than the 12 months for those treated with 90 Y-DOTATATE, although the difference did not reach statistical significance. 52 Furthermore, 177 Lu-DOTATATE was effective in alleviating the symptoms of carcinoid syndrome, including reductions in bowel movement frequency, flushing, and urinary 5-hydroxyindoleacetic acid excretion.

also in 111,027 other papers